## **DRUG DEVELOPMENT PIPELINE**





GENETIC
THERAPY
THERAPIES STILL
IN DEVELOPMENT

# RESTORE CFTR FUNCTION

- 4 THERAPIES AVAILABLE
- Elexacaftor + tezacaftor + ivacaftor (Trikafta®)
- Ivacaftor (Kalydeco®)
- Lumacaftor + ivacaftor (Orkambi®)
- Tezacaftor + ivacaftor (Symdeko®)

#### MUCOCILIARY CLEARANCE

- 3 THERAPIES AVAILABLE
- Dornase alfa (Pulmozyme®)
- Hypertonic saline
- Inhaled mannitol (Bronchitol®)

#### ANTI-INFLAMMATORY


- THERAPY AVAILABLE
- High dose ibuprofen for CF

#### ANTI-INFECTIVE

- 5 THERAPIES AVAILABLE
- Amikacin liposome inhalation suspension (Arikayce®)
- Azithromycin
- Aztreonam (Cayston®)
- Inhaled tobramycin
- Tobramycin inhaled powder (TOBI® Podhaler®)

#### NUTRITION/ GI/OTHER

- 3 THERAPIES AVAILABLE
- AquADEKs
- Pancrelipase enzyme products
- RELiZORB®



### **DRUG DEVELOPMENT PIPELINE**



© December 2023

PRE-CLINICAL Initial testing in laboratory	PHASE 1 Human safety trial	PHASE 2 Human safety & efficacy trial	PHASE 3 Definitive trial	AVAILABLE TO PATIENTS 🗹
4D-710 LUNAR®-CF SPL84 VX-522 mRNA			GENETIC Therapy	I LEBARIES STILL IN DEVELOPINENT
Carmine Gensaic Nanite Pioneerin ReCode T	iosciences Therapeutics g Medicines Therapeutics Therapeutics Bio		RESTORE CFTR Function	■ Ivacattor (Naivdecow)
ELX-02 SION-638	aftor + deutivacaftor  erapeutics Research		MUCOCILIARY Clearance	Dornase ana (Fulmozymew)
GDC-6988 (ETD002 Brensocatib LAU-7b			ANTI- Inflammatory	THERAPY AVAILABLE  High dose ibuprofen for CF
Inhaled colistin (Col Intravenous gallium AP-PA02 AR-501 (Panaecin™ BX004-A Inhaled nitric oxide Opelconazole SPI-1005 Lefamulin (Xenleta™ RSP-1502  Kinnear P TB Alliand Adruplipase (forme) ANG003	(LungFit™ GO)  M) Inhaled murepavadir harmaceuticals		ANTI- INFECTIVE NUTRITION/ GI/OTHER	<ul> <li>Aztreonam (Cayston®)</li> <li>Inhaled tobramycin</li> <li>Tobramycin inhaled powder (TOBI® Podhaler®)</li> </ul> THERAPIES AVAILABLE <ul> <li>Aguade</li> </ul>

To advance drug development and a search for a cure, the Cystic Fibrosis Foundation (CFF) has contracts with several companies to help fund the development of potential treatments and/or cures for cystic fibrosis. Pursuant to these contracts, CFF may receive milestone based payments, equity interests, royalties on the net sales of therapies, and/or other forms of consideration. Resulting revenue received by CFF is used in support of our mission. See "How Drugs Get on the Pipeline" at www.cff.org/howdrugsgetonthepipeline for more.